Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard
Executive Summary
Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor
You may also be interested in...
Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
The Arthritis Drugs Advisory Committee's negative review of Merck's Arcoxia could be more indicative of the increasingly challenging regulatory environment for "me too" products than concerns over the Vioxx follow-on's safety profile
Negative Arcoxia Review May Reflect Increasingly High Hurdle For Me-Toos
The Arthritis Drugs Advisory Committee's negative review of Merck's Arcoxia could be more indicative of the increasingly challenging regulatory environment for "me too" products than concerns over the Vioxx follow-on's safety profile
Arcoxia Needs Further Study In 1,000s Of Patients, Or Discontinuation – Cmte
Merck's COX-2 inhibitor Arcoxia requires significant additional clinical safety and efficacy evaluation prior to approval, members of FDA's Arthritis Drugs Advisory Committee said in recommending against approval of the Vioxx follow-on for treatment of osteoarthritis